Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

Schwartz, Gregory G., Olsson, Anders G., Abt, Markus, Ballantyne, Christie M., Barter, Philip J., Brumm, Jochen, Chaitman, Bernard R., Holme, Ingar M., Kallend, David, Leiter, Lawrence A., Leitersdorf, Eran, McMurray, John J.V., Mundl, Hardi, Nicholls, Stephen J., Shah, Prediman K., Tardif, Jean-Claude, Wright, R. Scott·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1206797

Cited by (1,004)

Items 801–900 of 1,004

Pitavastatin and HDL: Effects on plasma levels and function(s)
Angela Pirillo, Alberico Luigi Catapano · 2017 · Atherosclerosis Supplements
Reconstituted high-density lipoproteins promote wound repair and blood flow recovery in response to ischemia in aged mice
Tania Tsatralis, Anisyah Ridiandries, S. E. J. Robertson, Laura Z. Vanags, Yuen Ting Lam, Joanne T. M. Tan, Martin Ng, Christina A. Bursill · 2016 · Lipids in Health and Disease
Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport
Petra El Khoury, Elisa Waldmann, Thierry Huby, Julie Gall, Philippe Couvert, Jean‐Marc Lacorte, John Chapman, Éric Frisdal, Philippe Lesnik, Klaus Georg Parhofer et al. · 2015 · Arteriosclerosis Thrombosis and Vascular Biology
A new method for measuring cholesterol efflux capacity uses stable isotope-labeled, not radioactive-labeled, cholesterol
Tomo Shimizu, Osamu Miyazaki, Takeo Iwamoto, Tomoyuki Usui, Ryo Sato, Chika Hiraishi, Hiroshi Yoshida · 2019 · Journal of Lipid Research
Diabetes and Vascular Disease: Is It All About Glycemia?
Alessandra Vecchié, Fabrizio Montecucco, Federico Carbone, Franco Dallegri, Aldo Bonaventura · 2019 · Current Pharmaceutical Design
ApoE and apoC-III-defined HDL subtypes: a descriptive study of their lecithin cholesterol acyl transferase and cholesteryl ester transfer protein content and activity
Mateo Amaya-Montoya, Jairo A Pinzón-Cortés, Lina S Silva-Bermúdez, Daniel Ruiz Manco, Maria Camila Pérez-Matos, Mario A. Jiménez-Mora, Carlos Olimpo Mendivil · 2020 · Lipids in Health and Disease
Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib
Eric J. Niesor, Guy Boivin, Éric Rhéaume, Rong Shi, Véronique Lavoie, Nathalie Goyette, Marie-Ève Picard, Anne Perez, Fouzia Laghrissi‐Thode, Jean‐Claude Tardif · 2021 · ACS Omega
Relationship between circulating adipokines and cholesterol efflux in subjects with severe carotid atherosclerosis
Karina Gasbarrino, Anouar Hafiane, Ioanna Gianopoulos, Huaien Zheng, Christos Socrates Mantzoros, Stella Styliani Daskalopoulou · 2022 · Metabolism
Management of Low Levels of High-Density Lipoprotein-Cholesterol
Amit V. Khera, Jorge Plutzky · 2013 · Circulation
New and Emerging LDL Cholesterol–Lowering Drugs
Constantine E. Kosmas, William H. Frishman · 2014 · American Journal of Therapeutics
Searching for a successful HDL-based treatment strategy
Srinivasa T. Reddy, Mohamad Navab, Gattadahalli M. Anantharamaiah, Alan M. Fogelman · 2013 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Reduced high-density lipoprotein cholesterol: A valuable, independent prognostic marker in peripheral arterial disease
E. Martínez-Aguilar, Josune Orbe, Alejandro Fernández‐Montero, Sebastian Fernandez-Alonso, José Antonio Rodríguez, Leopoldo Fernandez‐Alonso, José Antonio Páramo, Carmen Roncal · 2017 · Journal of Vascular Surgery
Effects of isoflavone-containing soya protein onex vivocholesterol efflux, vascular function and blood markers of CVD risk in adults with moderately elevated blood pressure: a dose–response randomised controlled trial
Chesney K. Richter, Ann C. Skulas‐Ray, Jennifer A Fleming, Christina Link, Ratna Mukherjea, Elaine Susan Krul, Penny M. Kris‐Etherton · 2017 · British Journal Of Nutrition
Apolipoprotein A-I Reduces In-Stent Restenosis and Platelet Activation and Alters Neointimal Cellular Phenotype
Laura Z. Vanags, Joanne T. M. Tan, Keyvan Karimi Galougahi, Andreas Schaefer, Steven G. Wise, Andrew James Murphy, Ziad A. Ali, Christina A. Bursill · 2018 · JACC Basic to Translational Science
Subsequent Event Risk in Individuals With Established Coronary Heart Disease
Riyaz S. Patel, Vinicius Tragante, Amand Floriaan Schmidt, Raymond O. McCubrey, Michael Vaclav Holmes, Laurence J Howe, Kenan Direk, Axel Åkerblom, Karin Leander, Salim S. Virani et al. · 2019 · Circulation Genomic and Precision Medicine
Revisiting Reverse Cholesterol Transport in the Context of High-Density Lipoprotein Free Cholesterol Bioavailability
Corina Rosales, Baiba Kurins Gillard, Bingqing Xu, Antonio M. Gotto, Henry J. Pownall · 2019 · Methodist DeBakey Cardiovascular Journal
Cholesterol membrane content has a ubiquitous evolutionary function in immune cell activation: the role of HDL
Fabrizia Bonacina, Angela Pirillo, Alberico Luigi Catapano, Giuseppe Danilo Norata · 2019 · Current Opinion in Lipidology
Effects of Virgin Olive Oil and Phenol-Enriched Virgin Olive Oils on Lipoprotein Atherogenicity
Marta Farràs, Marina Canyelles, Montserrat Fitó, Joan Carles Escolá‐Gil · 2020 · Nutrients
HDL cholesterol and apolipoprotein A-I concentrations and risk of atherosclerotic cardiovascular disease: Human genetics to unravel causality
Ruth Frikke‐Schmidt · 2020 · Atherosclerosis
Cholesteryl Ester Transfer Protein and Lipid Metabolism and Cardiovascular Diseases
Helena C.F. Oliveira, Helena Fonseca Raposo · 2020 · Advances in experimental medicine and biology
Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial
Mark P. Metzinger, Suzanne Saldanha, Jaskeerat S. Gulati, Kershaw V. Patel, Ayea El‐Ghazali, Sneha Deodhar, Parag H. Joshi, Colby R. Ayers, Anand K. Rohatgi · 2020 · Journal of the American Heart Association
Rationale and Design of the Prevention of Cardiovascular Events in Ischemic Stroke Patients with High Risk of Cerebral Hemorrhage (Picasso) Study: A Randomized Controlled Trial
Keun‐Sik Hong, Bum Joon Kim, Juneyoung Lee, Sun Uck Kwon · 2015 · International Journal of Stroke
The role of HDL in plaque stabilization and regression
Jonathan E. Feig, Jessica Lori Feig, George Dangas · 2016 · Coronary Artery Disease
High density lipoprotein structure, function, and metabolism: a new Thematic Series
Kerry‐Anne Rye · 2013 · Journal of Lipid Research
CETP Inhibitors — A New Inning?
Robert Alexander Hegele · 2017 · New England Journal of Medicine
Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis
Masson, Walter, Barbagelata, Leandro, Lobo, Martin, Nogueira, Juan Patricio, Handelsman, Yehuda · 2025 · Journal of Clinical Lipidology
The association of HDL-cholesterol levels with incident major adverse cardiovascular events and mortality in 0.6 million individuals with type 2 diabetes: a population-based retrospective cohort study
David Tak Wai Lui, Lanlan Li, Xiaodong Liu, Xi Xiong, Eric Ho Man Tang, Chi‐Ho Lee, Yu Cho Woo, Brian Hung‐Hin Lang, Carlos King Ho Wong, K. C. B. Tan · 2024 · BMC Medicine
CETP inhibitors and cardiovascular disease: Time to think again
N.E. Miller · 2014 · F1000Research
Beyond statins: what to expect from add-on lipid regulating therapy?
Ulrich Laufs, William Weintraub, Chris J. Packard · 2013 · European Heart Journal
Review of biomarkers to assess the effects of switching from cigarettes to modified risk tobacco products
Michael J. Peck, Edward B. Sanders, Gerhard Scherer, Frank Lüdicke, Rolf Weitkunat · 2018 · Biomarkers
The therapeutic potential of CETP inhibitors: a patent review
Xinran Wang, Wei Li, Lijuan Hao, Honglei Xie, Chenzhou Hao, Chunchi Liu, Wenyan Li, Xuqiong Xiong, Dongmei Zhao · 2018 · Expert Opinion on Therapeutic Patents
CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction
Davide Capodanno, Roxana Mehran, Charles Michael Gibson, Dominick Joseph Angiolillo · 2018 · Expert Opinion on Investigational Drugs
Steering the Lipid Transfer To Unravel the Mechanism of Cholesteryl Ester Transfer Protein Inhibition
Sneha M. Dixit, Mohd Ahsan, Sanjib Senapati · 2019 · Biochemistry
High-density Lipoprotein-cholesterol Subfractions and Coronary Artery Calcium: The ELSA-Brasil Study
Giuliano Generoso, Isabela M. Benseñor, Raul Dias Santos, Henrique Lane Staniak, Rodolfo Sharovsky, Itamar S Santos, Alessandra Carvalho Goulart, Steven Richard Jones, Krishnaji R. Kulkarni, Michael Joseph Blaha et al. · 2019 · Archives of Medical Research
Higher oxidized high-density lipoprotein to apolipoprotein A-I ratio is associated with high-risk coronary plaque characteristics determined by CT angiography
Kazuki Suruga, Toru Miyoshi, Kazuhiko Kotani, Keishi Ichikawa, Takashi Miki, Kazuhiro Osawa, Kentaro Ejiri, Hironobu Toda, Kazufumi Nakamura, Hiroshi Morita et al. · 2020 · International Journal of Cardiology
HDL-C and Cardiovascular Risk: You Don't Need to Worry about Extremely High HDL-C Levels
Yun Kyung Cho, Chang Hee Jung · 2021 · Journal of Lipid and Atherosclerosis
Pathophysiology and inhibition of cholesteryl ester transfer protein for prevention of cardiovascular diseases: An update
Surojit Banerjee, Abhijit De · 2021 · Drug Discovery Today
High density lipoprotein in atherosclerosis and coronary heart disease: Where do we stand today?
Evangelia Zvintzou, Dimitra Sotiria Karampela, Angeliki Vakka, Eva Xepapadaki, Eleni A. Karavia, Aikaterini Hatziri, Panagiota C. Giannopoulou, Kyriakos E. Kypreos · 2021 · Vascular Pharmacology
Oxidized high-density lipoprotein accelerates atherosclerosis progression by inducing the imbalance between treg and teff in LDLR knockout mice
Ru Ding, Zhiqing He, Zhu Lin, Feng Wu, Feng Zhang, Zhang Jiayou, Ren Yusheng, Fan Min, Liang Chun, Zonggui Wu · 2015 · Apmis
The Role of Advanced Lipid Testing in the Prediction of Cardiovascular Disease
Alvin Chandra, Anand K. Rohatgi · 2014 · Current Atherosclerosis Reports
Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium–glucose co-transporter 2 inhibitors
Dario Rahelić, Eugen Javor, Tomo Lucijanić, Marko Skelin · 2016 · Annals of Medicine
Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype
Veronika Sanin, Vanessa Pfetsch, Wolfgang Köenig · 2017 · Current Cardiology Reports
Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?
Theodosios D. Filippatos, Anastazia A. Kei, Moses Elisaf · 2017 · Diseases
High-density lipoprotein cholesterol raising
Jonathan D. Schofield, Michael W. France, Basil J. Ammori, Yifen Liu, Handrean Soran · 2013 · Current Opinion in Cardiology
High-density lipoprotein particle concentration and subclinical atherosclerosis of the carotid arteries in Japanese men
Maryam Zaid, Akira Fujiyoshi, Katsuyuki Miura, Robert D. Abbott, Tomonori Okamura, Naoyuki Takashima, Sayuki Torii, Y. Saito, Takashi Hisamatsu, Naoko Miyagawa et al. · 2015 · Atherosclerosis
Cholesteryl Ester-Transfer Protein Inhibitors Stimulate Aldosterone Biosynthesis in Adipocytes through Nox-Dependent Processes
Francisco J. O. Rios, Karla Bianca Neves, Aurélie Nguyen Dinh Cat, Sarah Even, Roberto Palacios, Augusto C. I. Montezano, Rhian M. Touyz · 2015 · Journal of Pharmacology and Experimental Therapeutics
Mechanism of Inhibition of Cholesteryl Ester Transfer Protein by Small Molecule Inhibitors
Venkat R. Chirasani, Revathi Sankar, Sanjib Senapati · 2016 · The Journal of Physical Chemistry B
Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase
Branko Simic, Pavani Mocharla, Margot Crucet, Elena Osto, Adelheid Kratzer, Simona Stivala, Susan Kühnast, Thimoteus Speer, Petia Doycheva, Hans M. G. Princen et al. · 2017 · Atherosclerosis
Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E
John S. Millar, Michael E. Lassman, Tiffany A. Thomas, Rajasekhar Ramakrishnan, Patricia A. Jumes, Richard L. Dunbar, Emil M. deGoma, Amanda L. Baer, Wahida Karmally, Daniel S. Donovan et al. · 2017 · Journal of Lipid Research
Current status of lipid management in acute coronary syndrome
Koichiro Fujisue, Kenichi Tsujita · 2017 · Journal of Cardiology
Reduction of In-Stent Restenosis by Cholesteryl Ester Transfer Protein Inhibition
Ben J. Wu, Yue Li, Kwok Leung Ong, Yidan Sun, Sudichhya Shrestha, Liming Hou, Douglas G. Johns, Philip J. Barter, K.-A. Rye · 2017 · Arteriosclerosis Thrombosis and Vascular Biology
Genetic Variation in Sodium‐glucose Cotransporter 2 and Heart Failure
Julius L. Katzmann, Amy M. Mason, Winfried März, Marcus Edi Kleber, Alexander Niessner, Matthias Blüher, Thimoteus Speer, Ulrich Laufs · 2021 · Clinical Pharmacology & Therapeutics
Umbrella Review on Non-Statin Lipid-Lowering Therapy
Semira Abdi Beshir, Nadia Hussain, Asim Ahmed Elnour, Amira S. A. Said · 2021 · Journal of Cardiovascular Pharmacology and Therapeutics
Sphingolipids in HDL – Potential markers for adaptation to pregnancy?
Patamat Patanapirunhakit, Helén Karlsson, Monique T Mulder, Stefan Ljunggren, Delyth Graham, Dilys J. Freeman · 2021 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Bariatric Surgery-induced High-density Lipoprotein Functionality Enhancement Is Associated With Reduced Inflammation
Safwaan Adam, Jan Hoong Ho, Yifen Liu, Tarza Jamal Siahmansur, Kirk W. Siddals, Zohaib Iqbal, Shazli Azmi, Siba Senapati, John P. New, Maria Jeziorska et al. · 2022 · The Journal of Clinical Endocrinology & Metabolism
Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction
Serge Korjian, Syed Hassan A. Kazmi, Gerald Chi, Arzu Kalaycı, Jane Lee, Usama Talib, Samuel D. Wright, Danielle Duffy, Bronwyn A. Kingwell, Roxana Mehran et al. · 2023 · European Heart Journal - Cardiovascular Pharmacotherapy
Do blood metals influence lipid profiles? Findings of a cross-sectional population-based survey
Sabit Cakmak, Kimberly Mitchell, Anna O. Lukina, Robert Dales · 2023 · Environmental Research
Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factor
Marlys L. Koschinsky, Erik S.G. Stroes, Florian Kronenberg · 2023 · Pharmacological Research
Mouse Models of Disturbed HDL Metabolism
Menno Hoekstra, Miranda Van Eck · 2014 · Handbook of experimental pharmacology
HDL Cholesterol and Cardiovascular Outcomes: What Is the Evidence?
Melvyn Rubenfire, Robert D. Brook · 2013 · Current Cardiology Reports
Spotlight on HDL biology: new insights in metabolism, function, and translation
Daniel James Rader · 2014 · Cardiovascular Research
Significance of the percentage of cholesterol efflux capacity and total cholesterol efflux capacity in patients with or without coronary artery disease
Kenji Norimatsu, Takashi Kuwano, Shin‐ichiro Miura, Tomohiko Shimizu, Yuhei Shiga, Yasunori Suematsu, Yuiko Miyase, Sen Adachi, Ayumi Nakamura, Satoshi Imaizumi et al. · 2016 · Heart and Vessels
Effects of Bariatric Surgery on HDL Cholesterol
Idoia Genua, Analía Ramos, Francisca Caimari, Carmen Balagué, José Luis Sánchez‐Quesada, Antonio Pérez, Inka Miñambres · 2020 · Obesity Surgery
Will Lipidation of ApoA1 through Interaction with ABCA1 at the Intestinal Level Affect the Protective Functions of HDL?
Eric J. Niesor · 2015 · Biology
The positive relationship of serum paraoxonase-1 activity with apolipoprotein E is abrogated in metabolic syndrome
Robin P. F. Dullaart, Arjan J. Kwakernaak, Geesje M. Dallinga‐Thie · 2013 · Atherosclerosis
Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk
Vinicius Tragante, Folkert Wouter Asselbergs, Daniel I. Swerdlow, Tom Palmer, Jason H. Moore, Paul I. W. de Bakker, Brendan J. Keating, Michael Vaclav Holmes · 2016 · Human Genetics
The mystery of evacetrapib - why are CETP inhibitors failing?
Stephen James Nicholls, Kristen J. Bubb · 2020 · Expert Review of Cardiovascular Therapy
Which lipids should be analyzed for diagnostic workup and follow-up of patients with hyperlipidemias?
Langlois, Michel R., Nordestgaard, Børge G. · 2018 · Current Cardiology Reports
High-Density Lipoprotein Subclasses and Their Role in the Prevention and Treatment of Cardiovascular Disease: A Narrative Review
Qiaofei Chen, Ayiguli Abudukeremu, Kaiwen Li, Minglong Zheng, Hongwei Li, Tongsheng Huang, Canxia Huang, Kexin Wen, Yue Wang, Yuling Zhang · 2024 · International Journal of Molecular Sciences
High-Density Lipoprotein in Patients with Diabetic Kidney Disease: Friend or Foe?
Ke Liu, Mark E. Cooper, Zhonglin Chai, Fang Liu · 2025 · International Journal of Molecular Sciences
Inhibition of cholesteryl ester transfer protein by anacetrapib does not impair the anti-inflammatory properties of high density lipoprotein
Seongah Han, Lauretta LeVoci, Paul A. Fischer, Shengping Wang, Karen Gagen, Ying Chen, Dan Xie, Timothy S. Fisher, Anka G Ehrhardt, Andrea M. Peier et al. · 2012 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (Los Ángeles, California, Estados Unidos, 3-7 de noviembre de 2012)
Pablo Avanzas y, Antoni Bayés‐Genís, Leopoldo Pérez de Isla, Juan Manuel Sanchís, Magda Heras · 2012 · Revista Española de Cardiología
The application of multiple reaction monitoring and multi-analyte profiling to HDL proteins
Hussein N. Yassine, Angela Jackson, Chad R. Borges, Dean D. Billheimer, Hyunwook Koh, DEREK S. H. SMITH, Peter D. Reaven, Serrine S. Lau, Christoph H. Borchers · 2014 · Lipids in Health and Disease
LDL-Cholesterol: Standards of Treatment 2016: A German Perspective
Winfried März, Hubert Scharnagl, Ioanna Gouni‐Berthold, Günther Silbernagel, Alexander Dressel, Tanja B. Grammer, Ulf Landmesser, Hans Dieplinger, Eberhard Windler, Ulrich Laufs · 2016 · American Journal of Cardiovascular Drugs
Dyslipidemia induced inflammatory status, platelet activation and endothelial dysfunction in rabbits: Protective role of 10-Dehydrogingerdione
Mohamed Mahmoud Elseweidy, Rawia sarhan Amin, Hebatallah Husseini Atteia, Reham Raafat El-Zeiky, Naif Ahmed Al-Gabri · 2018 · Biomedicine & Pharmacotherapy
Differential Proteomics of Cardiovascular Risk and Coronary Artery Disease in Humans
Ele Ferrannini, Maria Laura Manca, Giulia Ferrannini, Felicita Andreotti, Daniele Andreini, Roberto Latini, Marco Magnoni, Stephen A. Williams, Attilio Maseri, Aldo Pietro Maggioni · 2022 · Frontiers in Cardiovascular Medicine
CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial
Charles Michael Gibson, Syed Hassan A. Kazmi, Serge Korjian, Gerald Chi, Adam T. Phillips, Sahar Memar Montazerin, Danielle Duffy, Bo Zheng, Mark A. Heise, Charles L. Liss et al. · 2022 · Journal of Cardiovascular Pharmacology and Therapeutics
Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia
Paul Lee, Robert Alexander Hegele · 2013 · Expert Opinion on Investigational Drugs
Targeting the Unstable Plaque in Acute Coronary Syndromes
Peter Lindsay Thompson, Stefan Mark Nidorf, John W. Eikelboom · 2013 · Clinical Therapeutics
HDL functionality and crystal-based sterile inflammation in atherosclerosis
Esin Eren, Hamit Yaşar Ellidağ, Özgür Aydın, Necat Yılmaz · 2014 · Clinica Chimica Acta
Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice
Thomas A. Bell, Mark J. Graham, Richard G. Lee, Adam E. Mullick, Wuxia Fu, Dan Norris, Rosanne M. Crooke · 2013 · Journal of Lipid Research
Variation in the Phosphoinositide 3-Kinase Gamma Gene Affects Plasma HDL-Cholesterol without Modification of Metabolic or Inflammatory Markers
Martin Kächele, Anita M. Hennige, Jürgen Machann, Anja Hieronimus, Apostolia Lamprinou, Fausto E Machicao, Fritz Schick, Andreas Fritsche, Norbert Stefan, Bernd Nürnberg et al. · 2015 · PLoS ONE
Translational atherosclerosis research: From experimental models to coronary artery disease in humans
Christian Albert Gleissner · 2016 · Atherosclerosis
Assessing Cardiovascular Risk and Testing in Type 2 Diabetes
Anum Saeed, Christie Mitchell Ballantyne · 2017 · Current Cardiology Reports
Strikingly Different Atheroprotective Effects of Apolipoprotein A-I in Early- Versus Late-Stage Atherosclerosis
Jamie Morton, Shisan Bao, Laura Z. Vanags, Tania Tsatralis, Anisyah Ridiandries, Chung‐Wah Siu, Kwong‐Man Ng, Joanne T. M. Tan, David Stephen Celermajer, Martin Ng et al. · 2018 · JACC Basic to Translational Science
Association between high-density lipoprotein subfractions and low-grade inflammation, insulin resistance, and metabolic syndrome components: The ELSA-Brasil study
Giuliano Generoso, Isabela M. Benseñor, Raul Dias Santos, Itamar S Santos, Alessandra Carvalho Goulart, Steven Richard Jones, Krishnaji R. Kulkarni, Michael Joseph Blaha, Peter Paul Toth, Paulo A. Lotufo et al. · 2018 · Journal of clinical lipidology
Relation between high density lipoprotein particles concentration and cardiovascular events: a meta-analysis
Yujing Wu, Zhijuan Fan, Yaqiong Tian, Shuang Liu, ShuYe Liu · 2018 · Lipids in Health and Disease
High prevalence of cardiovascular disease in South Asians: Central role for brown adipose tissue?
Mariëtte R. Boon, Leontine E. H. Bakker, Rianne A. D. van der Linden, Antoinette F. van Ouwerkerk, Pauline L. de Goeje, Jacqueline Counotte, Ingrid M. Jazet, Patrick C.N. Rensen · 2015 · Critical Reviews in Clinical Laboratory Sciences
Treatment of dyslipidemia
Andrew Maxwell Tonkin, Allison Byrnes · 2014 · F1000Prime Reports
Helical domains that mediate lipid solubilization and ABCA1-specific cholesterol efflux in apolipoproteins C-I and A-II
Loren E. Smith, Jere P. Segrest, William Sean Davidson · 2013 · Journal of Lipid Research
HDL-cholesterol, genetics, and coronary artery disease: the myth of the ‘good cholesterol’?
Ulf Landmesser, Stanley L. Hazen · 2018 · European Heart Journal
Innovation of Lipid‐Based Nanoparticles: the Design and Applications in the Cardiovascular Disease Management
Zhengying Gu, Tianbao Liu, Wutian Rao, Dan Li, Qinghang Zhang, Jinjie Dai, Lin Huang, Jiayi Wang, Xumin Hou · 2024 · Advanced Functional Materials
Comprehensive Review of Lipid Management in Chronic Kidney Disease and Hemodialysis Patients: Conventional Approaches, and Challenges for Cardiovascular Risk Reduction
Erica Abidor, Michel Al Achkar, Ibrahim Al Saidi, Tanvi Lather, Jennifer Jdaidani, Alaukika Agarwal, Suzanne El‐Sayegh · 2025 · Journal of Clinical Medicine
ApoA-I-Directed Therapies for the Management of Atherosclerosis
John S. Millar, Marina Cuchel · 2015 · Current Atherosclerosis Reports
Cholesteryl Ester Transfer Protein Inhibition Enhances Endothelial Repair and Improves Endothelial Function in the Rabbit
Ben J. Wu, Sudichhya Shrestha, Kwok Leung Ong, Douglas G. Johns, Liming Hou, Philip J. Barter, Kerry‐Anne Rye · 2015 · Arteriosclerosis Thrombosis and Vascular Biology
Type 1 Deiodinase Regulates ApoA-I Gene Expression and ApoA-I Synthesis Independent of Thyroid Hormone Signaling
Jing Liu, Antonio Hernández‐Ono, Mark J. Graham, Valerie Anne Galton, Henry N. Ginsberg · 2016 · Arteriosclerosis Thrombosis and Vascular Biology
Cholesteryl Ester Transfer Protein Inhibitors
Julian Hardy McLain, Andrew Jacob Alsterda, Rohit Romesh Arora · 2016 · Journal of Cardiovascular Pharmacology and Therapeutics
Associations of Arachidonic Acid Synthesis with Cardiovascular Risk Factors and Relation to Ischemic Heart Disease and Stroke: A Univariable and Multivariable Mendelian Randomization Study
Ting Zhang, Shiu Lun Au Yeung, Catherine Mary Schooling · 2021 · Nutrients
Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction
Gregory G. Schwartz, Robert Patrick Giugliano · 2022 · Current Opinion in Lipidology
Non-linear relationship between high-density lipoprotein cholesterol and incident diabetes mellitus: a secondary retrospective analysis based on a Japanese cohort study
Changchun Cao, Haofei Hu, Xiaodan Zheng, Xiaohua Zhang, Yulong Wang, Yongcheng He · 2022 · BMC Endocrine Disorders